GUILFORD, Conn., September 9, 2020 — InveniAI® LLC (InveniAI), a global leader in pioneering the application of artificial intelligence (AI) and machine learning (ML) to transform drug discovery and development, today announced that the Company will collaborate with PRISM BioLab Co. Ltd, (PRISM), a biotechnology company with proprietary small-molecule drug discovery technology, to build a pipeline of novel therapeutic candidates addressing diseases in the gut associated with the dysfunction of the gut-brain-axis and inflammasome dysregulation.
Partnership with Japan-based PRISM BioLab will enable the synthesis and development of proprietary therapeutic small-molecule candidates against molecular targets identified by InveniAI's AI platform – AlphaMeld®.
InveniAI will use its proprietary AlphaMeld® platform to identify and validate relevant novel targets that will be used to develop transformative therapies for gut-related diseases. PRISM BioLab will use its proprietary platform to design small-molecule candidates against targets validated by InveniAI. InveniAI will pursue human proof of concept for all candidate drugs.
Although significant knowledge has accumulated that proposes several gastrointestinal (GI) diseases such as Crohn's disease, ulcerative colitis, and irritable bowel syndrome arise due to disruption of the gut-brain-axis communication network and gut dysbiosis, the healthcare burden and unmet medical needs of GI diseases remain high with a $136 billion annual healthcare expenditure.
"The value of combining our AlphaMeld platform and PRISM's existing compound library and protein mimetics capabilities allows us to deploy a de-risked model to generate concepts at scale and seamlessly advance these programs through to human proof of concept at unprecedented speed and with a high probability of success," said Krishnan Nandabalan, Ph.D., President and CEO of InveniAI. "We remain the only company with several AI-generated candidates in clinical development, with the most advanced recently completing a successful Phase III study."